Phase II trial of diaziquone in patients with colon cancer

J. A. Neidhart, C. Erlichman, F. Robert, E. Velez-Garcia, J. F. Bender, J. Grillo-López

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Seventeen patients with metastatic colon cancer received diaziquone iv daily for 5 days repeated every 28 days. Based on recommended starting doses for phase II trials (6-8 mg/m2 daily x 5), the first six patients received 7 mg/m2/day x 5. Two of these patients were heavily pretreated with chemotherapy, two had received prior 5-FU alone, and two had received no prior chemotherapy. There were no responses and three septic deaths (both of the heavily pretreated patients and one 5-FU-only patient who received concurrent radiotherapy). Eleven subsequent patients received 5.5 mg/m2/day x 5. Nine had no prior therapy; two had received prior 5-FU. No antitumor responses were observed. Myelosuppression was again the major toxic effect. No further septic deaths occurred. Diaziquone in this dose and schedule had no antitumor activity in this group of patients.

Original languageEnglish (US)
Pages (from-to)215-217
Number of pages3
JournalCancer Treatment Reports
Volume69
Issue number2
StatePublished - 1985
Externally publishedYes

Fingerprint

diaziquone
Colonic Neoplasms
Fluorouracil
Drug Therapy
Poisons
Appointments and Schedules
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neidhart, J. A., Erlichman, C., Robert, F., Velez-Garcia, E., Bender, J. F., & Grillo-López, J. (1985). Phase II trial of diaziquone in patients with colon cancer. Cancer Treatment Reports, 69(2), 215-217.

Phase II trial of diaziquone in patients with colon cancer. / Neidhart, J. A.; Erlichman, C.; Robert, F.; Velez-Garcia, E.; Bender, J. F.; Grillo-López, J.

In: Cancer Treatment Reports, Vol. 69, No. 2, 1985, p. 215-217.

Research output: Contribution to journalArticle

Neidhart, JA, Erlichman, C, Robert, F, Velez-Garcia, E, Bender, JF & Grillo-López, J 1985, 'Phase II trial of diaziquone in patients with colon cancer', Cancer Treatment Reports, vol. 69, no. 2, pp. 215-217.
Neidhart JA, Erlichman C, Robert F, Velez-Garcia E, Bender JF, Grillo-López J. Phase II trial of diaziquone in patients with colon cancer. Cancer Treatment Reports. 1985;69(2):215-217.
Neidhart, J. A. ; Erlichman, C. ; Robert, F. ; Velez-Garcia, E. ; Bender, J. F. ; Grillo-López, J. / Phase II trial of diaziquone in patients with colon cancer. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 2. pp. 215-217.
@article{a86519550ec842d1afc5cd72bacac96c,
title = "Phase II trial of diaziquone in patients with colon cancer",
abstract = "Seventeen patients with metastatic colon cancer received diaziquone iv daily for 5 days repeated every 28 days. Based on recommended starting doses for phase II trials (6-8 mg/m2 daily x 5), the first six patients received 7 mg/m2/day x 5. Two of these patients were heavily pretreated with chemotherapy, two had received prior 5-FU alone, and two had received no prior chemotherapy. There were no responses and three septic deaths (both of the heavily pretreated patients and one 5-FU-only patient who received concurrent radiotherapy). Eleven subsequent patients received 5.5 mg/m2/day x 5. Nine had no prior therapy; two had received prior 5-FU. No antitumor responses were observed. Myelosuppression was again the major toxic effect. No further septic deaths occurred. Diaziquone in this dose and schedule had no antitumor activity in this group of patients.",
author = "Neidhart, {J. A.} and C. Erlichman and F. Robert and E. Velez-Garcia and Bender, {J. F.} and J. Grillo-L{\'o}pez",
year = "1985",
language = "English (US)",
volume = "69",
pages = "215--217",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Phase II trial of diaziquone in patients with colon cancer

AU - Neidhart, J. A.

AU - Erlichman, C.

AU - Robert, F.

AU - Velez-Garcia, E.

AU - Bender, J. F.

AU - Grillo-López, J.

PY - 1985

Y1 - 1985

N2 - Seventeen patients with metastatic colon cancer received diaziquone iv daily for 5 days repeated every 28 days. Based on recommended starting doses for phase II trials (6-8 mg/m2 daily x 5), the first six patients received 7 mg/m2/day x 5. Two of these patients were heavily pretreated with chemotherapy, two had received prior 5-FU alone, and two had received no prior chemotherapy. There were no responses and three septic deaths (both of the heavily pretreated patients and one 5-FU-only patient who received concurrent radiotherapy). Eleven subsequent patients received 5.5 mg/m2/day x 5. Nine had no prior therapy; two had received prior 5-FU. No antitumor responses were observed. Myelosuppression was again the major toxic effect. No further septic deaths occurred. Diaziquone in this dose and schedule had no antitumor activity in this group of patients.

AB - Seventeen patients with metastatic colon cancer received diaziquone iv daily for 5 days repeated every 28 days. Based on recommended starting doses for phase II trials (6-8 mg/m2 daily x 5), the first six patients received 7 mg/m2/day x 5. Two of these patients were heavily pretreated with chemotherapy, two had received prior 5-FU alone, and two had received no prior chemotherapy. There were no responses and three septic deaths (both of the heavily pretreated patients and one 5-FU-only patient who received concurrent radiotherapy). Eleven subsequent patients received 5.5 mg/m2/day x 5. Nine had no prior therapy; two had received prior 5-FU. No antitumor responses were observed. Myelosuppression was again the major toxic effect. No further septic deaths occurred. Diaziquone in this dose and schedule had no antitumor activity in this group of patients.

UR - http://www.scopus.com/inward/record.url?scp=0021997260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021997260&partnerID=8YFLogxK

M3 - Article

C2 - 3882229

AN - SCOPUS:0021997260

VL - 69

SP - 215

EP - 217

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -